PD-L1 in non-small-cell lung cancer: the third target for immunotherapy
Mené sur 144 patients atteints d'un cancer du poumon non à petites cellules de stade avancé ou métastatique, cet essai randomisé international de phase II compare l'efficacité, du point de vue de la survie globale, et la toxicité de l'atézolizumab par rapport au docétaxel, en fonction des niveaux d'expression de PD-L1 sur les cellules tumorales et les cellules immunitaires infiltrant les tumeurs
Advanced-stage non-small-cell lung cancer (NSCLC) has a dismal prognosis. At disease presentation, more than 50% of patients have metastatic disease and, despite advances in chemotherapy and targeted therapy, median overall survival is less than 1 year. For patients who progress on first-line standard therapies, docetaxel is the treatment of choice and is associated with a median survival of 7·5 months. With the emergence of immune checkpoint inhibitors, the prognosis for a fairly large proportion of patients might finally start to improve.
The Lancet , commentaire, 2015